Results 61 to 70 of about 280,195 (357)
Nanomedicine for the Treatment of Non-Hodgkin Lymphoma [PDF]
Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually.
Gandhi, B.Pharm, Tanvi
core +1 more source
Epstein-Barr virus (EBV) is a DNA virus which belongs to the Herpesviridae family, has been infected with 90% of the world’s population. EBV is transmitted through saliva and associated with different diseases such as Infectious Mononucleosis ...
Ala Habibian +6 more
doaj
Cerebral type MALT non Hodgkin lymphoma
Introduction: Non-Hodgkin's lymphomas generally have their origin in the lymphoid system, there is a great diversity of them, which makes their classification and definitive pathological diagnosis difficult.
Yaimara Zunen Hernández Puentes +3 more
doaj
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma
Chemotherapy and hematopoietic stem cell transplantation are effective treatments for most Hodgkin lymphoma patients, however there remains a need for better tumor-specific target therapy in Hodgkin lymphoma patients with refractory or relapsed disease ...
Ziduo Li +21 more
doaj +1 more source
Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma [PDF]
Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics.
Basso, Giuseppe +11 more
core +2 more sources
Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface
This study identifies a cancer‐specific interaction between CD47 and integrin αvβ3 that facilitates immune evasion. A rationally designed peptide, PSFL‐NK13, disrupts this axis, enhancing macrophage‐mediated phagocytosis and suppressing tumor growth without inducing anemia.
Peng‐Cheng Yu +12 more
wiley +1 more source
Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk.
Mara M. Epstein +11 more
doaj +1 more source
Lymphomas in Golestan province of Iran: Results of a population-based cancer registry [PDF]
Introduction: Malignancies of lymphoid cells can be divided into Hodgkin and non-Hodgkin lymphomas (NHL) on the basis of pathologic features, clinical manifestations and treatment.
Aarabi, M. +8 more
core
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma [PDF]
Key Points Combining phosphatidylinositol-3-kinase δ inhibition with rituximab, bendamustine, or both is feasible and active in relapsed iNHL.
Barrientos, Jacqueline C. +14 more
core +2 more sources
This study uses a high‐resolution DNA methylation reference panel for 19 immune cell‐types, as well as transcriptomic, metabolomic, and large population cohort data to show that age‐related epigenetic heterogeneity within monocytes correlates with inflammaging, biological age, and all‐causemortality, and does so more strongly than existing monocyte ...
Xiaolong Guo +17 more
wiley +1 more source

